Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)

• Status: Recruiting
• Trial end date: 2022-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of surfactant is not clear. This study aimed to determine whether ARDS neonate would benefit from surfactant when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• Treatments: Pulmonary Surfactants

Criteria

Inclusion Criteria:

1. infant less than 28 days

2. diagnosis of ARDS or RDS or both

3. informed parental consent has been obtained

Exclusion Criteria:

1. major congenital malformations or complex congenital heart disease or chromosomal abnormalities

2. transferred out of the neonatal intensive care unit without treatment

3. upper respiratory tract abnormalities